The Efficacy and Safety of Preoperative Chemotherapy With Triweekly Abraxane and Cyclophosphamide Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Therapy for Resectable Breast Cancer: A Multicenter Clinical Trial

Micro-Abstract Tri-weekly Abraxane has better outcomes than tri-weekly Cremophor-based taxol, and cyclophosphamide combined with taxane shows an enhanced antitumor effect. We showed excellent efficacy and safety of preoperative chemotherapy with TRI-ABC (tri-weekly Abraxane and cyclophosphamide) followed by FEC (5-fluorouracil, epirubicin and cyclophosphamide) for resectable breast cancer. Further clinical studies should be conducted to compare the tri-weekly Abraxane and cylophosphamide regimen with conventional taxane regimens.